Laura Benjamin
Director/Board Member at ALLARITY THERAPEUTICS, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thomas Jensen | M | 45 |
Allarity Therapeutics A/S
 Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | 20 years |
| Gerald McLaughlin | M | 56 |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | 2 years |
| Steen Meier Knudsen | M | 63 |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | 20 years |
| Joseph Vazzano | M | 40 |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | 1 years |
| Joan Brown | F | 71 |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | 3 years |
| Marie Foegh | M | 82 |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | 6 years |
| Chrystyna Stecyk | F | 61 |
Oncxerna Therapeutics, Inc.
 Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | - |
| Zuie Chin Huang | M | 59 |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | - |
| Peter Bisgaard | M | 50 |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | - |
| Hagop Youssoufian | M | 67 |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | 4 years |
| David Malek | M | 47 |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | 6 years |
| Sarah Wang | F | - |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | - |
| Yunjoon Kim | M | - |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | - |
| Rebecca Wolfe | F | - |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| James Cullem | M | 56 | 2 years | |
| Duncan Moore | M | 65 | 2 years | |
| Gail Maderis | F | 66 | 2 years | |
| David Roth | M | 61 | 1 years | |
| Robert Oliver | M | 65 | - | |
| Søren Jensen | M | 61 | 2 years | |
| Charles Ballantyne | M | 64 |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | 2 years |
| Matthew Osborne | M | - |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 22 | 100.00% |
| Denmark | 6 | 27.27% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Laura Benjamin
- Personal Network
